Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients

Thrombosis Research

Volumn 105, Issue 6, 2002, Pages 471-476

  Koo, Bon Hun ^a   Oh, Doyeun ^b   Chung, So Young ^b   Kim, Nam Keun ^b   Park, Seonyang ^c   Jang, Yangsoo ^a   Chung, Kwang Hoe ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Malignant tumor; von Willebrand factor (vWF); von Willebrand factor cleaving protease (vWF cp)

Indexed keywords

VON WILLEBRAND FACTOR; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; METALLOPROTEINASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD CHEMISTRY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; VON WILLEBRAND DISEASE; BLOOD; COLON TUMOR; DIMERIZATION; DISEASE COURSE; ENZYMOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADULT; AGED; COLONIC NEOPLASMS; DIMERIZATION; DISEASE PROGRESSION; FEMALE; HUMAN; MALE; METALLOENDOPEPTIDASES; MIDDLE AGE; NEOPLASM METASTASIS; NEOPLASMS; VON WILLEBRAND FACTOR; ADAM PROTEINS; HUMANS; MIDDLE AGED;

EID: 0037085694     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00053-1     Document Type: Article

References (33)

1. Inducible secretion of large, biologically potent von Willebrand factor multimers
2. Isolation and characterization of two domains of human von Willebrand factor that interact with fibrillar collagen types I and III
3. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: Affinity is related to multimeric size
4. Ristocetin - A new tool in the investigation of platelet aggregation
5. Venom coagglutinin: An activator of platelet aggregation dependent on von Willebrand factor
6. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation
7. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation
8. Multimeric composition of endothelial cell-derived von Willebrand factor
9. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
10. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
11. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
12. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura
13. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
14. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura
15. A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases
16. Tumor-induced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis
17. Murine tumor-induced platelet aggregation and coagulation: Mechanisms, inhibitors, and species differences
18. Characterization of tumor-induced platelet aggregation: The role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells
19. A GPIb alpha-related protein is expressed by fresh human breast carcinoma tissue and is regulated by a PKC-sensitive mechanism
20. Human breast carcinoma cells synthesize a protein immunorelated to platelet glycoprotein-Ib alpha with different functional properties
21. Platelet-tumor cell interaction with the subendothelial extracellular matrix: Relationship to cancer metastasis
22. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies
23. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease
24. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
25. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome
26. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
27. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: An explanation for platelet aggregation in thrombotic thrombocytopenic purpura
28. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura
29. A cathepsin-like cysteine proteinase proaggregating activity in thrombotic thrombocytopenic purpura
30. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo
31. Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases
32. Cleavage of human von Willebrand factor by platelet calcium-activated protease
33. Evidence that calpains and elastase do not produce the von Willebrand factor fragments present in normal plasma and IIA von Willebrand disease